CAR T-cell therapy recommended as earlier treatment line for RRMM
An advisory committee of the U.S. Food and Drug Administration (FDA) has unanimously recommended extending the approval of Janssen’s Carvykti (ciltacabtagene autoleucel) as an…
Myeloma
Approval of a Darzalex Faspro therapy combo is sought in Europe
Johnson & Johnson has applied to the European Medicines Agency (EMA) for approval of its under-the-skin formulation of Darzalex (daratumumab), called…
Myeloma Action Month to focus on bringing hope through action
Myeloma Action Month (MAM) is observed each March to call attention to multiple myeloma and the people affected by it, and this year’s…
FDA OKs less frequent Tecvayli dosing for treatment responders
The U.S. Food and Drug Administration (FDA) has cleared an every-other-week dosing regimen of Tecvayli (teclistamab) for relapsed or refractory (hard-to-treat) multiple myeloma…
Elrexfio now approved in Canada as recurring myeloma treatment
Health Canada has granted conditional approval to Pfizer’s Elrexfio (elranatamab-bcmm), expanding the list of countries where the medication can be used for adults with…
Blenrep delays disease progression by nearly 3X versus Darzalex
GlaxoSmithKline (GSK)’s Blenrep (belantamab mafodotin) significantly reduced by more than half the risk of disease progression or death in people with relapsed or refractory…
Regeneron seeking approval of linvoseltamab for RRMM in US, EU
The European Medicines Agency has agreed to review Regeneron Pharmaceuticals’ application seeking approval of its investigational therapy linvoseltamab for adults in Europe with relapsed…
Abecma wins CHMP’s thumbs up for use in earlier treatment lines
Bristol Myers Squibb has received a positive opinion from an arm of the European Medicines Agency (EMA) on the use of its CAR T-cell…
Treating hepatitis may improve patient outcomes in myeloma
A dysregulated immune response against viruses that cause hepatitis may lead to some cases of multiple myeloma (MM) — and in these cases, treating…
Obesity, smoking, and poor sleep raise risk of myeloma precursor
Obesity, a history of heavy smoking, and limited sleep are risk factors for developing monoclonal gammopathy of undetermined significance (MGUS), a precursor condition to…
Recent Posts
- Germany clears pelareorep pancreatic cancer trial continuation
- FDA grants orphan drug status to novel brain cancer treatment
- Medicaid expansion can raise demand for gynecologic cancer care
- Under-the-skin Sarclisa found as effective as approved formulation
- FDA gives LYT-200 fast track status as potential AML treatment